Antiangiogenic VEGF Isoform in Inflammatory Myopathies

Nila Volpi,1 Alessandra Pecorelli,2,3 Paola Lorenzoni,1 Francesco Di Lazzaro,1 Giuseppe Belmonte,1 Margherita Agliano,1 Luca Cantarini,1 Fabio Giannini,1 Giovanni Grasso,1 and Giuseppe Valacchi4,5

1 Department of Medicine, Surgery and Neuroscience, University of Siena, Via A. Moro 2, 53100 Siena, Italy
2 Department of Pharmacology and Experimental Therapeutics, University of Siena, Via A. Moro 2, 53100 Siena, Italy
3 Child Neuropsychiatry Unit, University Hospital AOUS, Viale M. Bracci 16, 53100 Siena, Italy
4 Department of Life Sciences and Biotechnologies, University of Ferrara, Via L. Borsari 46, 44121 Ferrara, Italy
5 Department of Food and Nutrition, Kyung Hee University, Seoul 130-701, Republic of Korea

Correspondence should be addressed to Nila Volpi; nila.volpi@unisi.it

Received 12 March 2013; Revised 1 May 2013; Accepted 15 May 2013

Objective. To investigate expression of vascular endothelial growth factor (VEGF) antiangiogenic isoform A-165b on human muscle in idiopathic inflammatory myopathies (IIM) and to compare distribution of angiogenic/antiangiogenic VEGFs, as isoforms shifts are described in other autoimmune disorders. Subjects and Methods. We analyzed VEGF-A165b and VEGF-A by western blot and immunohistochemistry on skeletal muscle biopsies from 21 patients affected with IIM (polymyositis, dermatomyositis, and inclusion body myositis) and 6 control muscle samples. TGF-β, a prominent VEGF inductor, was analogously evaluated. Intergroup differences of western blot bands density were statistically examined. Endomysial vascularization, inflammatory score, and muscle regeneration, as pathological parameters of IIM, were quantitatively determined and their levels were confronted with VEGF expression. Results. VEGF-A165b was significantly upregulated in IIM, as well as TGF-β. VEGF-A was diffusely expressed on unaffected myofibers, whereas regenerating/atrophic myofibers strongly reacted for both VEGF-A isoforms. Most inflammatory cells and endomysial vessels expressed both isoforms. VEGF-A165b levels were in positive correlation to inflammatory score, endomysial vascularization, and TGF-β. Conclusions. Our findings indicate skeletal muscle expression of antiangiogenic VEGF-A165b and preferential upregulation in IIM, suggesting that modulation of VEGF-A isoforms may occur in myositides.

1. Introduction

Idiopathic inflammatory myopathies (IIM) encompass three subsets: dermatomyositis (DM), polymyositis (PM), and sporadic inclusion body myositis (IBM) with distinct immunopathological patterns. In DM, complement deposition on endomysial capillaries, loss of microvessels, and mainly perivascular inflammation are observed, whereas PM and IBM show a T-cell invasion of muscle cells associated with degenerative features in IBM. Recently, necrotizing autoimmune myopathy (NAM), with scarce or no inflammation, has been recognized as a fourth IIM entity [1]. The expression of inflammatory effectors in IIM is extensively investigated, since pharmacological targeting of immunoregulatory factors is increasingly recognized as an effective treatment tool [2–4].

Vascular endothelial growth factor (VEGF) family comprises a group of potent endothelial cell mitogens. VEGF-A, an angiogenic growth factor, proinflammatory mediator, and promoter of vascular permeability, is produced by various cell types, among which are myocytes and inflammatory cells. Its expression is transcriptionally regulated by multiple molecules: growth factors, hormones, and oncogenes [5]. Alternative splicing from eight exons within the VEGF-A gene generates a family of proteins, named according to their amino acid number, VEGFxxx. VEGF family encompasses proangiogenicxxx and antiangiogenicxxx isoforms, originating by alternate splice site selection in the terminal exon. Molecules have identical length but differing C-terminal amino acid sequences and opposing biological effect on angiogenesis: proangiogenic VEGFxxx isoforms originate by
proximal splice site selection and antiangiogenic VEGF\textsubscript{xxx b} isoforms by distal splice site selection [6]. VEGF-A\textsubscript{165 b} is the first identified antiangiogenic VEGF molecule [6]. Inhibition of angiogenesis by VEGF\textsubscript{xxx b} isoforms is due to competitive receptor binding, inhibition of receptor phosphorylation, and downstream intracellular signalling [7].

In the present work, we investigated tissue localization of VEGF-A\textsubscript{165 b} and VEGF-A in IIM as well as transforming growth factor-\(\beta\) (TGF-\(\beta\)), involved in the angiogenic and proliferative processes and a prominent VEGF-A\textsubscript{165 b} inductor, along with pathological parameters of myositides.

2. Subjects and Methods

2.1. Patients and Diagnostic Procedures. Muscle samples were archival diagnostic biopsy specimens from twenty-one patients affected with IIM, diagnosed by current clinicopathological criteria [1], as DM (\(n = 8\)), PM (\(n = 6\)), or IBM (\(n = 7\)). Demographic data are presented in Table 1. As control samples, we processed biopsy muscle specimens (\(n = 6\)) from subjects complaining of muscle pain, or cramps, with normal or mildly increased levels of serum creatine kinase and normal or mild myopathic electromyographic findings. We selected as controls only subjects in which muscle histology, histochemistry, immunohistology, and ultrastructural morphology resulted as normal, ruling out inflammation, degeneration-regeneration, denervation, or changes suggestive of metabolic storage. All subjects signed an informed consent with allowance to scientific utilization of muscle samples for research purposes. Specimens were frozen in liquid nitrogen-cooled isopropanol and stored at \(-80^\circ\)C until use. Cryostat sections, 10 \(\mu\)m thick, were submitted to diagnostic routine histological and histochemical stains.

2.2. Western Blot Analysis. WB analysis in muscle samples from control subjects and IIM patients was performed following standard procedures. Muscle samples were lysed in radioimmunoprecipitation assay (RIPA) buffer; proteins (40 \(\mu\)g load) were separated by SDS-PAGE 4–20% Tris-Glycine Pre-Cast Gel (Invitrogen S.R.L., Milan, Italy) and transferred to a nitrocellulose membrane. After blocking, samples were incubated with the primary antibodies for VEGF-A (cod. MAB3734; Millipore Corporation, Billerica, MA, USA), VEGF-A\textsubscript{165 b} (Abcam Plc, Cambridge, UK), TGF-\(\beta\) (Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA), and \(\beta\)-actin (Cell Signaling Technology, Inc., Danvers, MA, USA) and then with the appropriate secondary antibodies. Bound antibodies were visualized by enhanced chemiluminescence (ECL Detection Kit, GE Healthcare, Milan, Italy), and the band densities were quantified using NIH image software by using \(\beta\)-actin band for normalization.

2.3. Immunohistochemistry. Immunohistochemistry for diagnostic analysis of inflammation (HLA-ABC, C5-b9, CD4, CD8, CD11b, CD20, CD20, CD45Ro—Dako, Glostrup, Denmark; Carpinentina, CA, USA) was carried out on 7 \(\mu\)m thick cryostat sections on silane-coated slides (StarFrost; Knittel Gläser, Braunschweig, Germany). Immunolocalization of VEGF-A and VEGF-A\textsubscript{165 b} was performed on consecutive sections. Immunohistochemistry for TGF-\(\beta\) and endothelial marker CD31 (Dako), for vessel detection, were also carried out. Regenerating fibres were identified by antifoetal myosin heavy chain antibody (Novocasta Laboratories Ltd, Newcastle upon Tyne, UK). Analysis was performed by immunoperoxidase technique, by HRP-labeled polymer (Dako), and 3,3’-diaminobenzidine (Sigma-Aldrich, Milan, Italy) for visualization. Negative controls by omission of the primary antibody were performed.

2.4. Quantitative Analysis on Immunohistochemical Slides. Morphometry was carried out by Zeiss AxioPlan2 microscope equipped with AxioVision 4.6 software (Carl Zeiss Vision GmbH, Hallbergmoos, Germany). The endomysial vessel density, the degree of inflammation, and the entity of muscle regeneration were evaluated, as histopathological parameters of myositis.

Densities of endomysial vessels was expressed as number/mm\(^2\) of muscle area by counting the whole sections immunostained for CD31. Inflammatory score was assessed on sections stained for marker of activated leukocytes CD45Ro. For each sample, three randomly selected fields at 100x magnification were analyzed by automatized colorimetric pixel evaluation, detecting the peroxidase reaction product. CD45Ro peroxidase labeled area and the area of the whole field were measured: inflammatory score was expressed as the CD45Ro+ percentage of the total area.

![Table 1: Demographic data.](image-url)

Table 1: Demographic data.

|                      | PM | DM | IBM | Controls |
|----------------------|----|----|-----|----------|
| No. of subjects      | 6  | 8  | 7   | 6        |
| Gender: M, F         | 1, 5 | 3, 5 | 6, 1 | 4, 3     |
| Biopsy site          | Vastus lateralis: 4 | Vastus lateralis: 6 | Vastus lateralis: 6 | Vastus lateralis: 7 |
|                      | Deltoi: 2     | Deltoi: 2     | Brachial biceps: 1 |          |
| Age at biopsy, years (range) | 61.33 ± 7.87 (53–63) | 58.25 ± 12.07 (42–72) | 72.43 ± 7.91 (61–85) | 45.42 ± 23.22 (18–73) |
| Symptoms before biopsy, months | 12.5 ± 5.6 | 14.6 ± 9 | 40 ± 11.8 | — |
| Immunotherapy before biopsy (1–4 months) prednisolone: 5–10 mg/day | 3/6 | 4/8 | 7/7 | — |
Regeneration index was expressed as the percentage of foetal myosin heavy chain reactive fibres by examination of at least 700 fibres.

2.5. Statistics. Data were evaluated by SPSS statistics software. IIM were examined as a whole versus controls and as single subgroups. Intergroup variabilities were analyzed by Mann-Whitney test for paired analysis, and analysis of variance was performed by Kruskal-Wallis test for multiple groups. Spearman rank test was used to analyze correlations between WB band densities and the other investigated pathological parameters. Significance was set at $P < 0.05$. Data were expressed as means ± SD.

3. Results

3.1. Western Blot

3.1.1. VEGF-A and VEGF-A$_{165b}$. The protein levels of both VEGF isoforms were higher in IIM subjects (Figure 1). An increase of circa 30% for VEGF-A and up to 2.5-fold for VEGF-A$_{165b}$ versus controls (Figure 1(b)) was observed.
VEGF-A165b was significantly upregulated in the IIM subgroups DM, IBM, and PM versus controls; analysis of intergroup variance evidenced significantly higher levels of VEGF-A165b in IBM versus PM and DM (Figure 1(c)). The ratio VEGF-A165b/VEGF-A was significantly increased in IIM (Figure 1(d)), indicating a preferential upregulation of the antiangiogenic subunit: IIM 0.70 ± 0.40 (min 0.15, max 2.09); ctrls: 0.31 ± 0.25 (min 0.03, max 0.68). PM and IBM subgroups were significantly different from controls (Figure 1(e)).

3.1.2. TGF-β. IIM samples displayed an almost 2-fold increase in TGF-β levels versus controls (Figure 2(b)), with statistical significance in all the IIM subsets (Figure 2(c)). TGF-β protein levels in IIM were positively related with both VEGF isoforms content (Figures 2(d) and 2(e)).

3.2. Immunohistology

3.2.1. VEGF-A, VEGF-A165b, and TGF-β Localization. Muscle fibres showed a constitutive diffuse cytoplasmic expression of VEGF-A, either in controls (Figure 3(a)) and in IIM (Figures 4(1b); 4(2b); 4(3b); 4(4a)). Cytoplasmic localization of VEGF-A165b was very faint in control muscle, where endomysial vessels appear the main source of the protein (Figure 3(b)) and in morphologically normal fibres of IIM (Figures 4(1c); 4(2c); 4(3c); 4(4b)). In myositis, atrophic and regenerating fibres (Figure 4(1a)), identified by foetal myosin (Figure 4(1d)), were strongly reactive for either isoforms. A milder VEGF-A165b upregulation was observed in most nonregenerating, morphologically normal fibres (Figure 4(1c)), with neolocalization of MHC I molecule
Figure 3: Immunohistological distribution of VEGF isoforms in control muscle. (a)–(c) Consecutive sections. Diffuse VEGF-A cytoplasmic stain of myofibers is observed (a); very mild cytoplasmic VEGF-A_{165b} reactivity, with stronger stain of endomysial sparse mononuclear cells and endomysial small vessels (b). No stain on negative control slide by omission of primary antibody (c).

Figure 5(b). Inflammatory score in IIM was in positive degree of inflammation compared to the other groups correlation with VEGF-A. IBM cases showed the highest 3.3.2. Inflammatory Score. VEGF-A expression was maintained (Figure 4). TGF-β and VEGF-A co-localization but a stronger diffuse immunostain and a positive VEGF-A localization in the terminal complex of complement (Figure 4) was associated with VEGF local decrease [9]. Therefore, the VEGF increase that we report in IIM is not biased, but rather stressed, by the younger median age of our noninflammatory controls.

The occurrence of regenerating fibres was highly variable among and within the subgroups (Figure 5(c)): IBM and PM showed higher regeneration percentage as compared to DM.

3.3.3. Regeneration Index. The occurrence of regenerating fibres was highly variable among and within the subgroups (Figure 5(c)): IBM and PM showed higher regeneration percentage as compared to DM.

The regeneration index was positively related to TGF-β protein level in the whole group of IIM ($r = 0.473$, $P = 0.03$) and to VEGF-A_{165b}/VEGF-A ratio ($r = 0.523$, $P = 0.012$).

4. Discussion

The present report demonstrates that VEGF-A_{165b} is expressed in human skeletal muscle and its level robustly increases in IIM.

Constitutive expression of VEGF by myocytes is found to be essential for regulation of capillarity [8] and, in aged humans, the lower density of endomysial capillaries is associated with VEGF local decrease [9]. Therefore, the VEGF increase that we report in IIM is not biased, but rather stressed, by the younger median age of our noninflammatory controls.

Increase of VEGF in toto in skeletal muscle following injury, in association with fibres regeneration, is documented [10].

A recent fundamental study highlighted increased muscle expression of VEGF-A in IIM, in correlation with clinicopathological stages of disease, and it also specifically addressed the issue of therapy influence [11]. Glucocorticoid treatment (3–6 months) in PM and DM lowered VEGF-A expression, which stayed anyway significantly higher than in controls, by decreasing the number of VEGF-A reactive capillaries and mononuclear inflammatory cells, as we also observed in our treated patients. Therefore a role of steroids is likely also in the modulation of muscle VEGF-A_{165b}, however, the highest levels of both VEGF isoforms were detected in our group of IBM patients, typically unresponsive to steroids [4], all submitted to 1–4 months glucocorticoid treatment, prior to biopsy and histological diagnosis.

The constitutive expression of antiangiogenic VEGF isoforms is highly variable (reviewed by [12]). They are downregulated in highly angiogenic tissues, such as placenta [13], but they may reach 90% of the total VEGF protein in colon [14].

3.3. Quantitative Analysis

3.3.1. Density of Endomysial Vessels. Variations of endomysial vascularization were detected, according to literature data. IBM cases showed a significantly higher vessel density than controls (Figure 5(a)). Analysis of variance among IIM subsets evidenced a significantly higher endomysial vascularization in IBM versus PM and DM.

Endomysial vessel density in IIM was in positive correlation with VEGF-A ($r = 0.585$, $P = 0.017$) and VEGF-A_{165b} levels ($r = 0.503$, $P = 0.047$), as well as with VEGF-A_{165b}/VEGF-A ratio ($r = 0.812$, $P < 0.001$).

3.3.2. Inflammatory Score. IBM cases showed the highest degree of inflammation compared to the other groups (Figure 5(b)). Inflammatory score in IIM was in positive correlation with VEGF-A_{165b} levels ($r = 0.630$, $P = 0.009$), as well as with vessel density ($r = 0.499$, $P = 0.049$).
Figure 4: Continued.
A previous study investigating antiangiogenic isoforms of VEGF-A in human muscle did not detect VEGF-A\textsubscript{165b}, basally or after submaximal exercise, in healthy subjects, by PCR [15], whereas previous PCR [6], and ELISA [16] identifications of VEGF\textsubscript{165b} in skeletal muscle are reported. As skeletal muscle is richly vascularized, either Western blot or ELISA, at the protein level, and PCR, at the mRNA level, do not rule out detection of endothelial molecules. As we agree that, within normal muscle, the antiangiogenic VEGF subunit is mainly expressed by endothelial cells, the events of inflammation and coexisting atrophy/regeneration in IIM seem to trigger a substantial VEGF\textsubscript{165b} upregulation in muscle. A basal constitutive VEGF-A\textsubscript{165b} synthesis by myocytes, against a diffusion from adjacent inflammatory cells, is also suggested by the absent stain, for either VEGF isoforms, in necrotic fibres. The specificity of the utilized VEGF-A\textsubscript{165b} antibody, directed against the antiangiogenic COOH-terminal sequence, was assessed by complete lack of recognition of angiogenic VEGF-A\textsubscript{165} protein isoform by WB, as documented by manufacturer (http://www.abcam.com/VEGF-165B-antibody-MRVL56-1-abt4994.html). The differences in the staining pattern of the two isoforms further support antibody specificity.

Studies addressing the alternate distal/proximal site splicing in human disease describe a splicing switch to pro-angiogenic isoform in angiogenesis-associated disorders, such as solid tumors and diabetic retinopathy [17, 18]. Oppositely, a selective upregulation of VEGF-A\textsubscript{165b} is reported in retinal detachment associated with proliferative vitreoretinopathy, glaucoma [19], and fibrosing autoimmune disorder systemic sclerosis [20, 21], where decrease of angiogenesis occurs.

In our IIM samples, a local VEGF-A\textsubscript{165b} preferential upregulation is suggested by the increased VEGF-A\textsubscript{165b}/VEGF-A ratio.

Research data on VEGF-A\textsubscript{165b} offer clues to elucidate its increase in IIM: growth factors and related signal pathways act on VEGF\textsubscript{xxx}/VEGF\textsubscript{xxxb} alternative splicing [5, 17], and pleiotropic fibrogenic TGF-\beta is a key factor in switch to distal site splice selection for synthesis of VEGF-A\textsubscript{165b} [5, 20]. In our IIM samples, as previously described [2, 22], TGF-\beta was upregulated, and we observed a positive correlation TGF-\beta/VEGF-A\textsubscript{165b} by western blot. Therefore, the peculiar VEGF-A\textsubscript{165b} staining of degenerating/regenerating fibres may be linked to molecular events of muscle regeneration, where upregulation of TGF-\beta occurs [23], as supported by correlation of extent of regeneration and VEGF-A\textsubscript{165b}/VEGF-A ratio. Nevertheless, the lack of a direct correlation VEGF-A/regeneration index and a milder VEGF-A\textsubscript{165b} localization in nonregenerating fibres neoeXpressing major histocompatibility complex-I, a change consistent with myofiber activation (reviewed in [24]), suggest that other factors contribute significantly to VEGF-A\textsubscript{165b} upregulation in IIM. Immunohistology shows that TGF-\beta reactive endothelium and inflammatory cells are also a prominent source of VEGF-A\textsubscript{165b}. The finding is associated to inflammatory score/VEGF-A\textsubscript{165b} and both VEGF isoforms/vessel density positive correlations.
Though our patients’ subgroups are numerically too small to allow general conclusions, IBM higher inflammatory score and density of endomysial vessels, an acknowledged pathological feature of IBM [3], which resulted in our study strictly related to VEGF-A165b/VEGF-A ratio, appear to concur to higher VEGF-A165b expression. This apparently controversial issue might depend on a negative feedback triggered by VEGF-A165b. In fact, as it has been proposed [6, 25], VEGF-A165b can inhibit VEGF-A-mediated proliferation and migration of endothelial cells, via a counterregulatory mechanism, limiting the rate of de novo muscle capillarization.

Moreover, hypoxia, a strong VEGF modulating agent [14, 21, 26, 27], due to microvascular involvement, has a role in all the major IIM subsets by activating circuitries of cytokines, adhesion molecules, and leukocyte recruitment [3]. Skeletal muscle reacts with increased VEGF-A gene expression to hypoxia caused by acute exercise [27]. As an inductor of TGF-\(\beta\) [28], hypoxia might result in an additional causative factor of local VEGF-A165b increase in IIM.

Interestingly, besides antiangiogenic effect, a cytoprotective activity of VEGF-A165b against ischaemic damage has been recently documented on colon epithelium [14] and on retinal epithelium and endothelium [29], so that its compound biological effects still need to be elucidated.

5. Conclusions

Local VEGF antiangiogenic switch in inflammation and necrosis/regeneration of skeletal muscle is likely to depend on a cohort of humoral and cellular effectors, possibly involved in tissue protection against inflammatory process.
As therapeutic modulation of VEGF isoforms is currently investigated in cancer [12, 14] and in angiogenic eye disorders [17], and considering a potential development in autoimmune disorder systemic sclerosis [20, 21], further studies are needed for a complete understanding of the balance between antiangiogenic and proangiogenic VEGF isoforms in inflammatory myopathies.

Conflict of Interests

The authors declare that they have no conflict of interests.

Authors’ Contribution

Nila Volpi and Giuseppe Valacchi equally contributed to the study.

References

[1] M. C. Dalakas, “Review: an update on inflammatory and autoimmune myopathies,” Neuropathology and Applied Neurobiology, vol. 37, no. 3, pp. 226–242, 2011.

[2] R. Raju and M. C. Dalakas, “Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVlG and biological validation of clinically relevant genes,” Brain, vol. 128, no. 8, pp. 1887–1896, 2005.

[3] C. Grundtman and I. E. Lundberg, “Vascular involvement in the pathogenesis of idiopathic inflammatory myopathies,” Autoimmunity, vol. 42, no. 7, pp. 615–626, 2009.

[4] M. C. Dalakas, “Immunotherapy of inflammatory myopathies: practical approach and future prospects,” Current Treatment Options in Neurology, vol. 13, no. 3, pp. 311–323, 2011.

[5] D. G. Nowak, J. Woolard, E. M. Amin et al., “Expression of pro- and anti-angiogenic isoforms of VEGF is differentially regulated by splicing and growth factors,” Journal of Cell Science, vol. 121, no. 20, pp. 3487–3495, 2008.

[6] D. O. Bates, T.-G. Cui, J. M. Doughty et al., “VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma,” Cancer Research, vol. 62, no. 14, pp. 4123–4131, 2002.

[7] J. Woolard, W.-Y. Wang, H. S. Bevan et al., “VEGF165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression,” Cancer Research, vol. 64, no. 21, pp. 7822–7835, 2004.

[8] M. I. Olffert, R. A. Howlett, K. Tang et al., “Muscle-specific VEGF deficiency greatly reduces exercise endurance in mice,” Journal of Physiology, vol. 587, no. 8, pp. 1755–1767, 2009.

[9] N. A. Ryan, K. A. Zwetsloot, L. M. Westerkamp, R. C. Hickner, W. E. Pofahl, and T. P. Gavin, “Lower skeletal muscle capillarization and VEGF expression in aged vs. young men,” Journal of Applied Physiology, vol. 100, no. 1, pp. 178–185, 2006.

[10] A. Wagatsuma, “Endogenous expression of angiogenesis-related factors in response to muscle injury,” Molecular and Cellular Biochemistry, vol. 298, no. 1-2, pp. 151–159, 2007.

[11] C. Grundtman, E. Tham, A.-K. Ulfgren, and I. E. Lundberg, “Vascular endothelial growth factor is highly expressed in muscle tissue of patients with polymyositis and patients with dermatomyositis,” Arthritis & Rheumatism, vol. 58, no. 10, pp. 3224–3238, 2008.

[12] Y. Qiu, C. Hoareau-Aveilla, S. Oltean, S. J. Harper, and D. O. Bates, “The anti-angiogenic isoforms of VEGF in health and disease,” Biochemical Society Transactions, vol. 37, no. 6, pp. 1207–1213, 2009.

[13] D. O. Bates, P. P. MacMillan, J. G. Manjaly et al., “The endogenous anti-angiogenic family of splice variants of VEGF, VEG-Fxxxb, are down-regulated in pre-eclamptic placenta at term,” Clinical Science, vol. 110, no. 5, pp. 575–585, 2006.

[14] A. H. R. Varey, E. S. Rennel, Y. Qiu et al., “VEGF165b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy,” British Journal of Cancer, vol. 98, no. 8, pp. 1366–1379, 2008.

[15] T. Gustafsson, H. Ameln, H. Fischer, C. J. Sundberg, J. A. Timmons, and E. Jansson, “VEGF-A splice variants and related receptor expression in human skeletal muscle following sub-maximal exercise,” Journal of Applied Physiology, vol. 98, no. 6, pp. 2137–2146, 2005.

[16] W. S. Jones, B. D. Duscha, J. L. Robbins et al., “Alteration in angiogenic and anti-angiogenic forms of vascular endothelial growth factor-A in skeletal muscle of patients with intermittent claudication following exercise training,” Vascular Medicine, vol. 17, no. 2, pp. 94–100, 2012.

[17] D. G. Nowak, E. M. Amin, E. S. Rennel et al., “Regulation of Vascular Endothelial Growth Factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: a novel therapeutic strategy for angiogenesis,” The Journal of Biological Chemistry, vol. 285, no. 8, pp. 5532–5540, 2010.

[18] R. M. Perrin, O. Konopatskaya, Y. Qiu, S. Harper, D. O. Bates, and A. J. Churchill, “Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor,” Diabetologia, vol. 48, no. 11, pp. 2422–2427, 2005.

[19] C. Ergorul, A. Ray, W. Huang, D. Darland, Z. K. Luo, and C. L. Grosskreutz, “Levels of vascular endothelial growth factor-A165b (VEGF-A165b) are elevated in experimental glaucoma,” Molecular Vision, vol. 14, pp. 1517–1524, 2008.

[20] M. Manetti, S. Guiducci, E. Romano et al., “Overexpression of VEGF165b, an inhibitory splice variant of vascular endothelial growth factor, leads to insufficient angiogenesis in patients with systemic sclerosis,” Circulation Research, vol. 109, no. 3, pp. e14–e26, 2011.

[21] M. Manetti, S. Guiducci, L. Iba-Manneschi, and M. Matsuć-Cerinč, “Impaired angiogenesis in systemic sclerosis: the emerging role of the antiangiogenic VEGF(165)b splice variant,” Trends in Cardiovascular Medicine, vol. 21, no. 7, pp. 204–210, 2011.

[22] P. Confalonieri, P. Bernasconi, F. Cornello, and R. Mantegazza, “Transforming growth factor-β1 in polymyositis and dermatomyositis correlates with fibrosis but not with mononuclear cell infiltrate,” Journal of Neuropathology & Experimental Neurology, vol. 56, no. 5, pp. 479–484, 1997.

[23] M. Marotta, Y. Sarria, C. Ruiz-Roig, F. Munell, and M. Roig-Quilis, “Laser microdissection-based expression analysis of key genes involved in muscle regeneration in mdx mice,” Neuromuscular Disorders, vol. 17, no. 9-10, pp. 707–718, 2007.

[24] P. Englund, E. Lindroos, I. Nennesmo, L. Klareskog, and I. E. Lundberg, “Skeletal muscle fibers express major histocompatibility complex class II antigens independently of inflammatory infiltrates in inflammatory myopathies,” American Journal of Pathology, vol. 159, no. 4, pp. 1263–1273, 2001.
[25] T.-G. Cui, R. R. Foster, M. Saleem et al., “Differentiated human podocytes endogenously express an inhibitory isoform of vascular endothelial growth factor (VEGF165b) mRNA and protein,” *American Journal of Physiology*, vol. 286, no. 4, pp. F767–F773, 2004.

[26] F. Esposito, O. Mathieu-Costello, P. L. Entin, P. D. Wagner, and R. S. Richardson, “The skeletal muscle VEGF mRNA response to acute exercise in patients with chronic heart failure,” *Growth Factors*, vol. 28, no. 2, pp. 139–147, 2010.

[27] T. Gustafsson, A. Puntschart, L. Kaijser, E. Jansson, and C. J. Sundberg, “Exercise-induced expression of angiogenesis-related transcription and growth factors in human skeletal muscle,” *American Journal of Physiology*, vol. 276, no. 2, pp. H679–H685, 1999.

[28] V. Falanga, S. W. Qian, D. Danielpour, M. H. Katz, A. B. Roberts, and M. B. Sporn, “Hypoxia upregulates the synthesis of TGF-β1 by human dermal fibroblasts,” *Journal of Investigative Dermatology*, vol. 97, no. 4, pp. 634–637, 1991.

[29] A. L. Magnussen, E. S. Rennel, J. Hua et al., “VEGF-A165B is cytoprotective and antiangiogenic in the retina,” *Investigative Ophthalmology and Visual Science*, vol. 51, no. 8, pp. 4273–4281, 2010.